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Abstract
Lipochitin oligosaccharides (LCOs) are signaling molecules required by
ecologically and agronomically important bacteria and fungi to establish symbioses
with diverse land plants. In plants, oligo-chitins and LCOs can differentially interact
with different lysin motif (LysM) receptors and affect innate immunity responses or
symbiosis-related pathways. In animals, oligo-chitins also induce innate immunity
and other physiological responses but LCO recognition has not been
demonstrated. Here LCO and LCO-like compounds are shown to be biologically
active in mammals in a structure dependent way through the modulation of
angiogenesis, a tightly-regulated process involving the induction and growth of new
blood vessels from existing vessels. The testing of 24 LCO, LCO-like or oligo-chitin
compounds resulted in structure-dependent effects on angiogenesis in vitro leading
to promotion, or inhibition or nil effects. Like plants, the mammalian LCO biological
activity depended upon the presence and type of terminal substitutions.
Un-substituted oligo-chitins of similar chain lengths were unable to modulate
angiogenesis indicating that mammalian cells, like plant cells, can distinguish
between LCOs and un-substituted oligo-chitins. The cellular mode-of-action of the
biologically active LCOs in mammals was determined. The stimulation or inhibition
of endothelial cell adhesion to vitronectin or fibronectin correlated with their pro- or
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anti-angiogenic activity. Importantly, novel and more easily synthesised LCO-like
disaccharide molecules were also biologically active and de-acetylated chitobiose
was shown to be the primary structural basis of recognition. Given this, simpler
chitin disaccharides derivatives based on the structure of biologically active LCOs
were synthesised and purified and these showed biological activity in mammalian
cells. Since important chronic disease states are linked to either insufficient or
excessive angiogenesis, LCO and LCO-like molecules may have the potential to be
a new, carbohydrate-based class of therapeutics for modulating angiogenesis.
Introduction
Lipochitin oligosaccharides (LCOs) are natural products synthesised by
prokaryotic nitrogen fixing bacteria (generically called ‘‘rhizobia’’) and eukaryotic
arbuscular mycorrhizal (AM) fungi. These naturally occurring molecules act as
microbial signals that are required to establish nitrogen-fixing nodule formation
and mycorrhization respectively. These symbiotic interactions are of paramount
ecological and agronomic importance and contribute a significant proportion of
biologically-available nitrogen and phosphorous to agronomic systems
respectively [1, 2]. The legume-rhizobial symbiosis evolved relatively recently
(circa 60 million years ago) whereas the AM symbiosis is more ancient (circa 460
million years old) and widespread and there is considerable genetic overlap in the
signal transduction pathways that underpin both interactions [3]. Since 70–90%
of ancient and recently-evolved land plants can establish mycorrhization, LCO
recognition by plants is widespread [1, 3].
Rhizobial and fungal LCOs comprise of three to five b-1,4-linked
N-acetylglucosamine residues. In addition, they have an N-linked acyl
substitution at the non-reducing end and can often have modifications to the
C6 position of the reducing end N-acetly glucosamine residue. Rhizobia
synthesise LCOs by first making a de-acetylated chitin-oligomer by the
combined action of an oligo-chitin synthase (NODC) and an LCO de-acetylase
(NODB), which removes an acetyl group from the non-reducing end residue
[4]. Subsequently, the terminal residues can be decorated with assorted
substitutions which results in a wide structural diversity of rhizobial LCOs
[1, 5] with molecular masses between 1,000–1,500 Da [5]. In legumes, the
lengths of the chitin backbone and terminal substitutions greatly influence the
extent and specificity of LCO recognition by lysin motif (LysM) type receptors
[1, 6, 7, 8]. The LCO substitutions that influence the extent and specificity of
recognition leading to symbiotic interactions include
non-reducing-end, N-linked fatty acids (C16–C18) and reducing-end, O-linked
sugars or sulphate [1, 5, 6, 7, 9]. Recently, the chitin backbone of the LCO has
been shown to interact with its corresponding LysM receptor [7]. In contrast to
rhizobial and AM LCOs, different plant LysM-type receptors (e.g., LYK3 and
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LYK4) preferentially recognise chitin oligomers as microbe-associated mole-
cular patterns (MAMPs) and this induces an innate, ‘general-immune’
response [10, 11, 12]. Moreover, it has been shown that LYK3 in Arabidopsis
retains a residual ability to recognise LCOs but instead of innate immunity
being induced this interaction results in a suppression of innate immunity
[13]. Therefore, although LCOs and chitin oligomers may share an affinity for
chitin-motif recognising receptors the down-stream responses induced are
different.
Although LCO and, in particular, chitin-like molecules are widespread in
nature, mammals are not known to make chitins or chitin-like molecules
although they encode chitin synthase genes (e.g., DG42 [14]) which have
functions akin to NODC. In addition, like plants, mammals also recognise chitin
oligomers as MAMPs, and this also leads to the induction of an innate immune
[12, 15, 16] and other responses [17, 18]. Recently, it has been recognised that
LysM domain-containing proteins [19] and several glycoside hydrolase (GH)
family proteins (e.g., GH18) [20, 21] occur in the genomes of vertebrates but their
functions have not been fully elucidated. The ligands for the mammalian
LysM-domain containing proteins are not known but the GH family proteins
have chitin-binding and/or chitinase activity. One GH protein, YKL-40, is a
growth factor that induces cell proliferation by activating protein kinase signalling
and YKL-40 over-expression enhances the migration of human macrophage and
endothelial cells [22, 23]. In contrast to mammals, cyprinid fish not only appear
to synthesise chitin oligosaccharides de novo, but chitooligosacharides also appear
to play a role in their early development [14, 24]. Chitin recognition leads to
induction of innate immunity and there are reports that medium sized chitin
macro-particles (but not small-sized particles) may be linked to a possible role for
these chitin particles in asthma and allergy pathogenesis [25]. However, to our
knowledge, no reports have been made of toxicity for short chain chitin-based
molecules in mammals or vertebrates and chitins and chitosans are commonly
used as dietary supplements.
Angiogenesis is a complex, multi-stepped and highly regulated process in
mammals that involves endothelial cells (ECs) and has essential roles in
development, reproduction and repair. In addition, a plethora of important
diseases are associated with excessive or insufficient angiogenesis including solid
tumour formation, age-related macular degeneration, diabetic retinopathy,
atherosclerosis, peptic ulcers, rheumatoid arthritis, hypertension and ischemic
conditions [26, 27, 28, 29]. Therefore, biotechnological research has targeted
angiogenesis to identify new therapeutics. Most studies have focused on
discovering anti-angiogenic molecules and there has been progress in utilising
anti-angiogenic therapies in treating cancer and age related macular degeneration
[26]. Several clinically approved anti-angiogenic therapies include the use the
anti-angiogenic VEGF antibody (Avastin), VEGF receptor kinase inhibitors
(Sunitinib, Pazopanib, Sorafenib and Vandetanib) and the age-related macular
degeneration therapeutics ranibizumab and pegaptanib [30]. Pro-angiogenic
therapies have received less attention however, there is a pressing need to develop
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a pipeline of potential pro-angiogenic therapeutics to treat conditions such as
coronary and peripheral artery disease especially since clinical trials done so far
with existing drug candidates have lacked efficacy [31, 32].
During in vivo angiogenesis, the ECs that form new blood vessels from existing
vessels re-activate, migrate, proliferate and reorganise into tubes. Several
biological assays have been developed to assess candidate angiogenesis
therapeutics [33] but not all of them incorporate all of the four EC-associated
activities required for forming new blood vessels. However, the rat aorta ring
assay, which is widely used as a screen for anti-angiogenic activity, involves EC
re-activation, migration, proliferation and reorganisation and as a result of these
processes the formation of EC-derived micro-capillaries occur over a longer time
course than other biological assays [34]. Therefore, although the rat aorta ring
assay is ex vivo it is considered to more closely mimic in vivo conditions and it has
been used to successfully identify the anti-angiogenic therapeutic, Muparfostat
(PI-88), which is already in phase III cancer trials [34]. We show here that
adjustments to the concentration of heat inactivated foetal bovine serum can be
made in this widely used bioassay so that the anti- or pro-angiogenic effects of an
added compound on EC cells can be monitored (measured by determining the
speed and extent of angiogenesis over time). Other commonly used in vitro assays
examine the individual component steps of angiogenesis and are used to define
the cellular mode-of-action of a particular compound over a shorter time frame
[33].
Since plants and animals share the capacity to recognise chitin oligomers as
MAMPs [12] and LCOs are recognised by oligo-chitin receptors in Arabidopsis
[13], we hypothesized that mammalian cells would also detect LCOs and, if so,
that this might reflect a more widespread ability of oligochitin receptors to
interact with LCOs in nature. The ex vivo rat aorta ring angiogenesis assay was
used to assess this possibility. Using this assay, we discovered that certain
naturally-occurring LCOs, but not chitin oligomers, affected angiogenesis in a
structure-dependent manner in vitro. Therefore, we synthesised or assessed a
broader range of naturally occurring LCOs or ‘LCO-like’-molecules for
angiogenesis-regulating activity to determine the structural requirement for
this activity. Structure-activity assays identified the molecular constraints for
LCO- or LCO-like molecules to have effects on angiogenesis. The cellular
mode-of-action was determined using in vitro biological assays that tested
individual cellular components of angiogenesis (e.g., EC-reactivation,
EC-adhesion, or EC-migration). Finally, since a de-acetylated chitobiose (but
not chitobiose) was found to be biologically active, a synthesis was devised to
generate novel derivatives of this disaccharide that have LCO-like substitutions
as a route to develop a pipeline of potential therapeutics. The results showed
that these disaccharides may provide cheaper and more-readily-synthesised
candidates for future angiogenesis therapeutics based on the structures of
LCOs.
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Materials and Methods
Animal Ethics
The experiments conducted in this manuscript were performed under the
Australian National University Animal Experimentation Ethics Committee
stipulation A2011/35. The Institutional ethics committee specifically approved
this study.
Rat aorta ring assays
Aortic segments (1 mm; 9 month-old Fischer rats) were cultured in a gel-fibrin
matrix using six replicates per treatment [35]. Vessel outgrowths were
microscopically quantified after 5–7 days in the presence/absence of compounds
(Fig. 1) in Medium 199 containing 20% or 5% heat inactivated foetal bovine
serum (HIFBS; Sigma) for anti-angiogenic or pro-angiogenic activity, respectively
[36]. In 20% HIFBS, endothelial cell tubes ramify over 5 days and anti-angiogenic
activity retards tube formation prior to day 5. In sub-optimal HIFBS (5%),
endothelial cell tubes form over 7 days and pro-angiogenic or anti-angiogenic
activity can be observed at days 5, 6 and 7. The compounds tested were dissolved
in 50% HPLC grade acetonitrile and diluted at least 1:100 in supplemented
medium M199. Control cultures received medium with the diluent but without
the test substance or with the anti-angiogenic control, Muparfostat (PI-88 [34]),
at 100 mg/ml, which is its therapeutic dose in anti-cancer trials. The use of
Muparfostat in assays represents an additional control. Select compounds were
also tested at 10 or 1 mg/ml.
In vitro integrin-mediated attachment and cell migration assays
Human microvessel endothelial cells (HMECs) and human umbilical vein
endothelial cells (HUVECs) were assessed for enhanced or inhibited attachment to
fibronectin or vitronectin using the Rose Bengal assay [37]. A scratch-wound
migration assay was used to test the speed of closure of disrupted confluent
HUVEC monolayers [38]. HUVEC (46104 cells/well) were added to 48-well
plates in 300 ml/well of M199 medium, supplemented with 20% HIFBS, 0.24 mg/
ml gentamycin, 2 mM L-glutamine, 0.04 mg/ml ECGS (endothelial cell growth
supplement) and 0.135 mg/ml heparin and incubated at 37 C˚ in 5% CO2 until
confluent. The HUVEC monolayers were wounded, rinsed twice with 300 ml/well
of culture medium before 300 ml/well of medium was added with, or without, the
test compound. Wound recovery was photographed several times daily using an
Olympus IX81 CellR microscope and quantified using NIH Image J software.
Compounds were tested at 25 mg/ml in these in vitro assays.
LCO and LCO-like molecules
LCO and LCO-like compounds were generated in transgenic E. coli
[39, 40, 41, 42, 43, 44, 45, 46, 47] unless stated otherwise in Fig. 1 or synthesised as
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Fig. 1. Angiogenesis modulating activity of compounds determined by the rat aorta ring angiogenesis
assay. The generic structure indicates the positions of the substitutions, R1–R5, for the 24 compounds tested.
Compounds activities were measured as a % of untreated control: positive values represent enhanced
angiogenesis; negative values represent inhibited angiogenesis. PI-88 (Muparfostat; 100 mg/ml) was included
in all experiments as an anti-angiogenesis control. This compound is in phase III cancer trials and used
therapeutically at these concentrations [34]. In multiple assays PI-88 typically inhibited angiogenesis by 45–
65%. The Table includes results for the 24 LCO and LCO-like compounds only which were accumulated from
the results of multiple experiments each with mock- and Muparfostat-treated controls. Chitin oligomers were
purchased from Sapphire Chemicals and Compound 12 from Ciba Geigy. Compounds 11, 13–16 were
synthesised to purity and confirmed by high resolution mass spectrometry and NMR (Fig. S2 and Methods S1
in S1 File). All other compounds were synthesised as described [40, 58]. Compound 11 was also derived
independently from the supernatant of transgenic E. coli. The benzamide of compound 6 is described in Fig.
S1 in S1 File; the benzamide of compound 15 has an O-linked aliphatic C13H27. All compounds were tested at
100 mg/ml unless otherwise stated. NSE5no significant effect. *p,0.05; **p,0.01, ***p,0.001. Compound
24 was provided by Prof. William Broughton (University Gene´ve, Switzerland).
doi:10.1371/journal.pone.0112635.g001
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stated below. The structure and purity of the molecules used in this study was
confirmed by mass spectrometry as previously described [39, 40, 41, 42, 43,
44, 45, 46, 47]. The purity and integrity of newly described molecules are detailed
below.
Synthesis of compounds 11, 13, 14, 15 and 16
Five disaccharides (compounds 11, 13–16) [48] were synthesised starting from
commercially available product 29 (azido sugar 4-methoxyphenyl 2-azido-4,6-
O-benzylidene-2-deoxy-b-D-glucopyranoside) (Fig. S2 in S1 File). Selective
deprotection/N-acetylation of product 33 yielded disaccharides b-1-4
GlcNAc-GlcN and b-1-4 GlcN-GlcNAc (compounds 11 and 13; [48] Fig. 1).
Compounds 14, 15 and 16 (Fig. 1) were derived from compound 11. Final
product structures were verified by 1H- and 13C-NMR and high resolution
mass spectroscopy. Fig. S2 and Methods S1 in S1 File show details of the
experimental procedures and analytical data for the synthesis of compounds
11, 13–16.
Statistical Analysis
Data and results are reported as means ¡ SE. Statistical significance was
measured using two tailed t-test for Fig. 1, or one or two-way ANOVA, as
appropriate, using the GraphPad prism 5.04 and Instat software programs
(GraphPad Software, San Diego, CA). P values less than 0.05 were considered
statistically significant.
Results and Discussion
Soybean LCOs affect the development of mammalian endothelial
cells (ECs) ex vivo
Twenty-four LCO, LCO-like or chitin oligomer molecules were synthesised or
obtained and quantitatively and qualitatively screened in vitro for pro- or anti-
angiogenic effects on microvessel growth from rat aorta segments (Fig. 1). The
compounds used were fully synthesised (compounds 11, 13–16), or partially
synthesised after first purifying precursors from the supernatants of Escherichia
coli harbouring rhizobial LCO genes (i.e. for compounds 1–3, 5–10, 22,
23)[40, 41], isolated directly from the supernatants of Escherichia coli harbouring
rhizobial LCO genes (compounds 4, 11) [40, 41], obtained from commercial
sources (compounds 12, 17–21) or isolated directly from rhizobial secretions
(compound 24; Fig. 1; Methods). The LCOs used included naturally-occurring
structures with known and specific biological activity for soybean (compounds 1
and 2) or Medicago (compound 24). The artificial LCO-like molecules used
included de-acetylated chitin pentasaccharide derivatives each with non-naturally
occurring m-benzamide- or phenyl-acetyl-substitutions to the non-reducing
terminus [40] (Fig. 1; Fig. S1 in S1 File). Using the results from the structure
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activity relationships of larger LCO molecules, smaller and more-readily-
synthesised chito-disaccharides (compounds 11, 13–16) were synthesised and
tested (Fig. 1; Methods, Fig. S2 in S1 File).
The well-characterised rat aorta biological assay which generates EC-derived
‘‘tubes’’ akin to micro-capillaries was used to assess the activity of various
compounds (Fig. 1). Compounds 1 and 2 were chitopentamers similar to
naturally-occurring LCOs that have biological activity on soybean (e.g.,
compound 1–2) [49] and contained an N-linked non-reducing end acylation and
a reducing end fucose or methyl-fucose. Compounds 1 and 2 were shown to
possess anti-angiogenic activity akin to the control anti-angiogenic and cancer
therapeutic compound Muparfostat (also known as PI-88; Fig. 1). Removing the
fucosyl substitutions from compounds 1 and 2 rendered the resulting product
(compound 3) inactive. In addition, LCO-like compounds comparable to
compounds 1 and 2, but which lacked acylation, gave weak anti-angiogenic
(compounds 4–5), or nil activity (compounds 23–23). Compounds with sulfate
modifications to the reducing terminus, including the Medicago active LCO
compound 24, were also inactive. Importantly, un-substituted chitin oligomers of
two to six residues in length were inactive (compounds 17–21; Fig. 1). The length
of the oligo-chitin chain in the un-substituted chitin ologomers mirrored the
length of N-acetyl glucosamine residues occurring in the LCO molecules tested.
Collectively, these results show that, like plants, mammalian ECs can distinguish
between LCOs and chitin oligosaccharides, even though these molecules share an
oligo-chitin-like backbone. The results suggest that LCO structural specificity
(e.g., acylation and fucosylation) is required for strong anti-angiogenic activity on
ECs and the most biologically active LCO molecules strongly resembled structures
which affect soybean plants.
ECs also recognise LCO-like molecules with synthetic acyl groups
Since the most potent LCOs possessed a fatty acid substitution to the non-
reducing end, we tested if this modification could be substituted by non-
naturally-occurring benzamide or phenylacetyl groups as the ability of these
molecules bearing these modifications to bind LCO receptors in plants has been
demonstrated [40]. These synthetic LCOs were made using transgenic E. coli
harbouring the rhizobial genes, nodC and nodB, with and without nodZ, to
produce the precursor molecules before the artificial groups were added by a
separate synthetic step [40]. Strains containing nodC and nodB do not produce
rhizobial-type LCOs but instead produced oligo-chitin-like derivatives (mostly
pentamers) devoid of the N-acetyl group on the non-reducing terminal residue.
NODZ, which is encoded by a transferase gene [49], can add fucose or
methylfucose to the reducing end residue but also, occasionally, to an internal
N-acetylglucosamine (e.g., compound 9; Fig. 1). Purification of these fucosylated
or methyfucosylated oligo-chitin-like derivatives enabled the subsequent chemical
additions of either m-benzamide or phenylacetyl substitutions to the non-
reducing end to generate the synthetic LCO compounds 6–10 (Fig. 1) [40].
Plant Symbiosis Signalling Molecules Modulate Angiogenesis
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Compound 6 (m-benzamide; a mimic of a C16:2 substitution; Fig. S1 in S1 File)
was amongst the most potent anti-angiogenic compounds and its structure and
activity was consistently stronger than compounds 1 and 2 and Muparfostat
(Fig. 1). By contrast, compounds 7–9, which contain phenylacetyl substitutions
instead of a fatty acid or m-benzamide group (Fig. 1), were pro-angiogenic
(Fig. 2A; Fig. S1 in S1 File). This indicated that the size and nature of the non-
reducing-end substitutions were important for the type of LCO biological activity
imparted when these compounds were exposed to mammalian cells. More
importantly, by changing the nature of the non-reducing end substitution to a
phenylacetyl group instead of a longer acyl derivative, molecules with the opposite
biological activity could be generated.
We tested the requirement for reducing end fucosylation for the biological
activity of these synthetic LCO-like compounds by generating compound 10
which lacked fucosylation. This compound was inactive (Fig. 1; Fig. S1 in S1 File)
Fig. 2. Assessment of the sprouting of tubes from rat aorta rings induced by pro-and anti-angiogenic
LCO and LCO-like compounds. (A B) Tube sprouting induced by pro-angiogenic compounds 7–9 (A)
compound 11 (B) compared to mock-treated controls (‘‘C’’). (C). Tube sprouting induced by the anti-
angiogenic disaccharide compounds, 14 and 15, relative to a mock-treated control (‘‘C’’) and compound 16.
(*5p,0.05; **5p,0.01; ***5p,0.001; one-way ANOVA).
doi:10.1371/journal.pone.0112635.g002
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and this was consistent with the inactivity of compound 3, which also lacked
fucosylation. Therefore, like plants [5, 7, 9, 50], the most biologically active LCO
or LCO-like molecules in mammals, required appropriate terminal substitutions
and the nature of the substitutions influenced whether anti-angiogenic, pro-
angiogenic or inactive molecules were generated.
A de-acetylated chitobiose is biologically active
Although pentamers of LCO precursors can be readily synthesised by, and
extracted from, transgenic E. coli [39], they are challenging and expensive to
synthesise chemically as they require complex protection and de-protection
reactions for each sugar molecule added. In addition, E. coli is an unsuitable
system for generating potential therapeutics due to the presence of its
lipopolysaccharide, which is biologically active in humans [51], and this may
contaminate the supernatants of E. coli from which LCOs are initially extracted.
Therefore, from a synthesis perspective, smaller and simpler LCO-like molecules
are desirable. To examine this possibility, compound 11, a de-acetylated
disaccharide, was synthesised firstly in vivo using E. coli harbouring nodC and a
chitinase [39]. Surprisingly, compound 11 (Gln-GlnAc; b 1–4 linkage), was
pro-angiogenic (Fig. 2B, Fig. 1) even though it lacked acyl or sugar substitutions
to the termini.
To validate the result obtained with the E. coli-derived compound 11, and to
examine the structural requirements for its pro-angiogenic activity, compound 11
and its isomer (compound 13; GlnAc-Gln) were chemically synthesised (see Fig.
S2 and Methods S1 in S1 File for a detailed description of the synthesis) and
compared their activity with that of two other structurally similar disaccharides
(compounds 12 and 17). The independently-derived and synthetic compound 11
was as pro-angiogenic as compound 11 isolated from E. coli culture secretions.
This result not only validated the original result with the E. coli-supernatant-
derived compound 11 but also negated any possibility of trace E. coli molecules,
present in the supernatant, such as lipopolysaccharide [51], being involved in the
biological activity of the original compound 11. Therefore, these results
demonstrate that compound 11, irrespective of whether it was derived from E. coli
or via chemical synthesis (Fig. 2B; Fig. 1), represents a biologically-active and
structurally simple compound. Importantly, this compound is more-readily-
synthesisable in vitro than the larger LCO molecules made using transgenic E. coli
derivatives combined with an additional chemical synthesis step.
To determine how specific the activity of compound 11 was, its biological
activity was compared to chito-like disaccharides with structural similarity. The
activity of compound 11 was specific since three structurally-related isomers were
inactive. These included the synthesised compound 13 (GlnAc-Gln, Fig. S2 in S1
File) as well as compound 17 (GlnAc-GlnAc; chitobiose) and compound 12 (Gln-
Gln); both compound 17 and 12 are commercially available. The differential
activity of compounds 11 (Gln-GlnAc) compared to compounds 12 (Gln-Gln), 13
(GlnAc-Gln) and 17 (GlnAc-GlnAc) demonstrated a specific structural require-
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ment for pro-angiogenic activity. The activity of compound 11 could in part be
explained by a reported inability of chitinases to hydrolyse chitobiose [52] and
this is consistent with this compound 11 being the dominant product of the E. coli
strain harbouring nodC and a chitinase [39]. In addition, the results clearly
demonstrate that de-acetylation of the non-reducing end of compound 11 was a
strict requirement for its biological activity and that the de-acetylated chitin
backbone was a primary structural basis of recognition.
Acylated derivatives of compound 11 are biologically active
The activity and structure of compound 11 provided an opportunity to chemically
synthesise several non-naturally-occurring, disaccharide structural variants
(compounds 14–16; Fig. S2 and Methods S1 in S1 File) based on the LCO and
LCO-like molecules we tested with biological activity (e.g., compounds 1 and 2
and 6–10). Compounds 14–16 contained synthetic lipophilic side chains designed
to impart a longer retention time in vivo than that expected for compound 11. As
expected, compounds 14 and 15 were strongly anti-angiogenic (Fig. 2C; Fig. 1)
whereas compound 16 was, unexpectedly, inactive (Fig. 2C; Fig. 1). Nevertheless,
since compounds 14 and 15 were anti-angiogenic and compound 11 was pro-
angiogenic, it is clear that the biological activity of these shorter and novel
disaccharides is also affected by the structure and type of substitution occurring at
the non-reducing end. The finding of biological activity in mammals with these
smaller, easier-to-synthesise disaccharides opens the possibility of producing a
range of smaller LCO-like derivatives as potential therapeutics.
LCOs affect EC cell adhesion to ECM components
The cellular mode-of-action of selected LCOs was explored using biological assays
that emulate individual mechanistic components of angiogenesis [26, 29]. These
LCOs were tested in vitro for effects on EC adhesion to extracellular matrix
(ECM) components (Fig. 3A–C; Fig. 4A–B), a process that is usually integrin
dependent [53], and EC migration (Fig. 4A, B). The results suggested that the
LCO mode-of-action was mediated through inhibition or enhancement of EC
attachment to the ECM components, fibronectin and vitronectin (Fig. 3A–C). For
example, the anti-angiogenic compound 14 inhibited adhesion of HMEC
(Fig. 3A, B) and HUVEC (Fig. 4A, B) to fibronectin and vitronectin whereas
compound 15 inhibited adhesion of HMEC to fibronectin. In contrast, the pro-
angiogenic compounds 7–9 and 11, enhanced the rate of HMEC adhesion to
vitronectin (Fig. 3C). Therefore, LCO enhancement or inhibition of angiogenesis
correlated with their activity in the cell adhesion assay. No compounds tested
significantly affected the speed of cell migration in a wound recovery assay in vitro
after disrupted HUVEC monolayers were treated with several compounds
(Fig. 4C–D). Since migration of ECs is one of the earliest steps in angiogenesis,
this suggests that enhancement or inhibition of angiogenesis by compounds with
biological activity occurred after this step. Of note, compound 14 exhibited a
Plant Symbiosis Signalling Molecules Modulate Angiogenesis
PLOS ONE | DOI:10.1371/journal.pone.0112635 December 23, 2014 11 / 18
stronger anti-angiogenic activity (Fig. 2C; Fig. 1) than compounds 15 and 16, and
this was consistent with its greater anti-adhesive activity (Fig. 3A, B). This is
unlikely to be a toxic effect as, to our knowledge, low molecular weight chitin
based molecules do not have toxicity in animal systems.
Fig. 3. LCO enhancement or inhibition of integrin-mediated attachment of endothelial cells to
extracellular matrix components in vitro. (A–B) A 2-way ANOVA analyses showed the anti-angiogenic
compound 14 inhibits HMEC (human microvascular endothelial cell) attachment to immobilised fibronectin
and vitronectin whereas compound 15 affects HMEC attachment to fibronectin only (compounds added at
25 mg/ml, adhesion 60 min). The vitronectin and fibronectin concentrations refer to the concentrations used to
coat the plates. (C) One-way ANOVA analyses showed pro-angiogenic compounds 7 and 8 enhances HMEC
attachment to vitronectin after incubation for 40 min. ‘‘C’’ designates control in A–C. *(p,0.05); **(p,0.01),
***(p,0.001), ****(p,0.0001). Vertical bars represent SEM (n56).
doi:10.1371/journal.pone.0112635.g003
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Conclusions and perspectives
Plants are able to distinguish between different LCO structures and oligo-chitins
through specific interactions with different LysM receptors to impart develop-
mental and innate immunity responses respectively [1, 7, 13, 54]. In addition,
recent results show that chitin-recognising LysM receptors retain residual ability
to interact with LCOs, but suppression of an innate immunity response resulted
rather than induction [13]. The results presented here show that animal cells, like
plants, can also distinguish between LCOs and oligo-chitins of comparable
carbohydrate backbone size to impart different responses. This occurs even
though chitin or chitin-like molecules are not known to be synthesised by
mammals. Second, LCOs with different terminal residues can impart opposite
biological effects upon mammalian ECs. Some impart anti-angiogenic effects and
Fig. 4. Effects of selected LCO and LCO-like compounds HUVEC adhesion to ECM components and
cell migration. (A, B) Effect of compounds 14, 15 and 16 on the attachment of HUVEC to fibronectin-or
vitronectin-coated plates, respectively. A 2-way ANOVA analyses showed only compound 14 significantly
affected integrin-mediated attachment. (C, D) No compounds tested significantly affected cell migration in a
wound recovery assay after disrupted HUVEC monolayers were treated with compounds 8, 9 or 11 or 14, 15
or 16, respectively. ‘‘C’’ designates control in A–D. (***5p,0.001, ****5p,0.0001; one way ANOVA).
doi:10.1371/journal.pone.0112635.g004
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others pro-angiogenic effects. The differential activity of these LCOs is broadly
consistent with the different structure-dependent responses imparted by LCOs
and chitins in plants.
Higher concentrations of LCO and LCO-like compounds were required to
trigger activity in mammalian cells than in plants. Despite this, the concentrations
used still fall into a range that could be used in a therapeutic setting. For example,
similar concentrations of the carbohydrate based therapeutic Muparfostat are
used in successful clinical trials. In addition, our results also show there is a
correlation between angiogenesis modulating activity in mammals and interac-
tions of ECs with ECM components in vitro.
Unlike plants, a mammalian receptor for LCO, LCO-like and the shorter
disaccharide molecules is not known. However, chitin-binding proteins and
chitinases of the GH family, which are predicted to be secreted, are involved in
several physiological processes in mammals [15, 16, 18, 55]. In addition, chitin
oligomers have been shown to trigger intracellular kinase signalling cascades.
Chitin induction of innate immune cells associated with allergic responses occurs
independently of the Toll-like-receptor 4 (TLR4) and myeloid differentiation
factor 88 (MyD88) [15]. Apart from the GH family of proteins, vertebrates also
encode LysM domain containing proteins, several of which incorporate single pass
transmembrane and GRAM (Glucosyltransferases, Rab-like GTPase activators and
Myotubularins) domains [19], but not kinase domains. Chitin-binding proteins
and chitinases of the GH family and mammalian LysM domain proteins should be
explored as mammalian candidates for receptors for LCO and LCO-like
molecules. Zebrafish might be a useful system to test LCO biological activity and
tissue specificity in a vertebrate model. This is because (a) zebrafish produce
endogenous chito-oligosaccharides that appear to play a role in early
embryogenesis [14, 24] (although this is not demonstrated in mammals) and (b)
zebra fish LysM domain and chitinase proteins show specific expression patterns
in the nervous system during embryogenesis [19] and the accessibility of
embryogenesis in this system has distinct advantages.
The pro-angiogenesis activities of compound 11, a de-acetylated chitin
disaccharide, and compounds 7 and 9, are key findings since the efficacy of
current pro-angiogenic therapies is not ideal [31, 32]. However, compound 11
lacks the lipophilic side chain found in LCOs and, although it may be resistant to
chitinase degradation [52] the half-life of this compound in vivo is likely to be
brief due to rapid excretion. Therefore, the routes for synthesising the novel
lipophilic variants of compound 11 that we devised (see Methods S1 in File S1)
are important, albeit this resulted only in anti-angiogenic derivatives being made.
Of these, compound 14 displayed strong anti-angiogenic activity in vitro and
further studies of structural analogues of this compound are warranted. Based on
the disaccharide structures synthesised and their activity in vitro, a route to
making chitin oligosaccharide compounds of potential therapeutic value has been
identified and this should be of wide interest. Therefore, the derivatives of the
disaccharide compounds identified in this study could be modelled and tested for
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therapeutic efficacy by using in vivo systems. Therefore, LCOs join a growing class
of short carbohydrate-based molecules with therapeutic potential [56, 57].
Supporting Information
S1 File. Supporting Information. Fig. S1, Structure of artificial LCO-like
compounds. Fig. S2, Details of the synthesis steps and reaction conditions used
for the production of compounds 11, 13, 14 15 and 16. Methods S1, Experimental
procedures for generating compounds 14, 15 and 16 and NMR spectra of all
compounds used in synthesis reactions.
doi:10.1371/journal.pone.0112635.s001 (DOCX)
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